Analyst Ratings For NASDAQ:CDTX – Cidara Therapeutics (NASDAQ:CDTX)
Today, NASDAQ:CDTX – Cidara Therapeutics (NASDAQ:CDTX) stock received an upgrade by WBB Securities from Hold ➝ Buy.
Some recent analyst ratings include
- 5/23/2018-WBB Securities Upgrade from a “Hold ➝ Buy” rating to a “” rating.
- 5/16/2017-Wedbush Reiterated Rating of Outperform.
- 4/29/2017-BTIG Research Reiterated Rating of Buy.
- 4/20/2017-Raymond James initiated coverage with a Strong-Buy rating.
- 4/12/2017-Ladenburg Thalmann initiated coverage with a Buy ➝ Buy rating.
Recent Insider Trading Activity For NASDAQ:CDTX – Cidara Therapeutics (NASDAQ:CDTX)
NASDAQ:CDTX – Cidara Therapeutics (NASDAQ:CDTX) has insider ownership of 15.20% and institutional ownership of 62.48%.
- On 11/15/2017 Target N V Biotech, Major Shareholder, bought 60,000 with an average share price of $7.57 per share and the total transaction amounting to $454,200.00.
- On 9/12/2017 Jeffrey Stein, CEO, bought 7,350 with an average share price of $6.79 per share and the total transaction amounting to $49,906.50.
- On 6/7/2017 Taylor Sandison, Insider, bought 20,000 with an average share price of $5.90 per share and the total transaction amounting to $118,000.00.
- On 6/5/2017 Jeffrey Stein, CEO, bought 15,000 with an average share price of $5.95 per share and the total transaction amounting to $89,250.00.
- On 3/31/2017 Jeffrey Stein, CEO, bought 12,900 with an average share price of $7.75 per share and the total transaction amounting to $99,975.00.
- On 3/31/2017 Kevin Forrest, Insider, bought 12,500 with an average share price of $7.75 per share and the total transaction amounting to $96,875.00.
- On 5/20/2016 Jeffrey Stein, CEO, bought 4,310 with an average share price of $11.51 per share and the total transaction amounting to $49,608.10.
Recent Trading Activity for NASDAQ:CDTX – Cidara Therapeutics (NASDAQ:CDTX)
Shares of NASDAQ:CDTX – Cidara Therapeutics closed the previous trading session at 5.15 up +0.25 5.10% with 5.449999809265137 shares trading hands.